Merck Joins TRANSVAC2 Project to Advance Vaccine Development and Manufacturing

- As part of the EU’s Horizon 2020 programme, TRANSVAC2 provides training on simplifying vaccine production and development

- Merck will conduct process development skills training at the M Lab™ Collaboration Center in Molsheim, France

Darmstadt, Germany, May 20, 2019 /PRNewswire/ -- Merck KGaA, a leading global science and technology company (Merck) Announced participation todayVaccine Formulation Institute(Vaccine Formulation Research Institute) andEuropean Vaccine Initiative(European Vaccine Initiative) collaborative projectsTRANSVAC2, offering training courses on vaccine process development. TRANSVAC2 is part of the European Union’s “Horizon 2020 Programme” (Horizon 2020) an infrastructure cooperation project.

Udit Batra, Member of the Executive Board of Merck KGaA and CEO of the Life Science businessUdit Batra) stated: “Participating in this project is a natural choice for our long-term focus on accelerating vaccine development and production. Through the TRANSVAC2 program, we are able to apply our vaccine R&D expertise to this critical area.”

byEuropean CommissionWith funding from the European Commission (EC), TRANSVAC2 strengthens European vaccine research and training, enhances the sustainability of EC vaccine initiatives by deploying permanent research infrastructure for early-stage vaccine development, and thereby accelerates vaccine development. Merck has been included in the list of collaborators under the TRANSVAC2 program.

As part of this project, Merck will hold two-day training courses in 2019 and 2021 for applicants evaluated by the TRANSVAC2 Selection Panel at the facility recently established by Merck in Molsheim, France.M Lab™ Collaborative CenterTraining. Participants will experience simulated laboratory workflows, which help them acquire the essential skills required for process development and familiarize themselves with single-use technologies.

Merck is focused on identifying effective ways to accelerate vaccine development and manufacturing, including collaborating with leading research institutions and industry partners to introduce new technologies that can significantly boost the global vaccine sector. To achieve this goal, Merck will fully leverage its internal manufacturing expertise, as well as its process knowledge in the preparation of viral vaccines and vectors.

Follow MerckTwitter @Merckgroup、Facebook@MerckGroup andLinkedIn。

All Merck press releases are distributed via email and are also available on the Merck website. Please log inwww.merckgroup.com/subscribeRegister online to modify your preferences or discontinue this service.